Cognito Therapeutics vs Eikon Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.
About
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.
About
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.